Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it

Page 7 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.

• Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 DiabetesCompletedNCT07541456Phase 4
• Adiponectin in Patients With Metabolic DisordersCompletedNCT07539584Not applicable
• Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting ConditionsCompletedNCT07479108Not applicable
• A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without FoodCompletedNCT07404137Phase 1
• Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast ConditionCompletedNCT07372118Phase 1
• A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.CompletedNCT07363707Phase 4
• SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and AnemiaCompletedNCT07344922Phase 3
• Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver DiseaseCompletedNCT07338331Not applicable
• Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsActive, not recruitingNCT07325435Phase 4
• Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.CompletedNCT07266779Phase 1
• Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgCompletedNCT07266766Phase 1
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Active, not recruitingNCT07222917Phase 2
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated TabletsCompletedNCT07213895Phase 1
• Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy AdultsCompletedNCT07213310Phase 1
• Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEFCompletedNCT07169981Phase 2
• The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and ObesityCompletedNCT07120828Phase 4
• Empagliflozin on Patients With Preserved Heart FailureCompletedNCT07112274Not applicable
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)Active, not recruitingNCT07107945Phase 3
• Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk FactorsCompletedNCT07077525Phase 4
• The Effect of Dapagliflozin on Patients With CardiomyopathyCompletedNCT07076615Phase 4
• To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.CompletedNCT07039890Phase 1
• A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and TogetherCompletedNCT07035457Phase 1
• Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled CancersActive, not recruitingNCT07033585Phase 2/3
• Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).Active, not recruitingNCT07020377Phase 1/2
• A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.CompletedNCT06979388Phase 1
• A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With FoodCompletedNCT06962826Phase 1
• Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes MellitusCompletedNCT06952231Phase 3
• A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaActive, not recruitingNCT06942910Phase 2
• Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen TensionActive, not recruitingNCT06933355Phase 4
• Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsCompletedNCT06932159Phase 1
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseCompletedNCT06926660Phase 2
• Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard TreatmentCompletedNCT06915870Not applicable
• Dapagliflozin to Prevent Anthracycline-Induced CardiotoxicityCompletedNCT06888505Phase 2
• Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
• Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular EdemaCompletedNCT06845163Phase 2
• HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed TherapyTerminatedNCT06844669Phase 2
• Evaluation of Empagliflozin vs Standard Care in Veterans With PrediabetesCompletedNCT06828731Phase 1
• Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 InhibitorsCompletedNCT06825156Phase 4
• Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCTTerminatedNCT06818305Phase 2
• Effects of Sodium-Glucose Co-transporter 2 Inhibitors on InflammationCompletedNCT06812429Early Phase 1
• Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart FailureCompletedNCT06783166Phase 2/3
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesCompletedNCT06762314Phase 2
• Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of LifeCompletedNCT06759077Phase 3
• Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 InhibitorsCompletedNCT06753994Phase 1
• Dapagliflozin as Prophylaxis for Glucocorticoid-Induced HyperglycemiaActive, not recruitingNCT06748105Phase 2
• SGLT2i in Diabetic Patients with Renal TransplantationActive, not recruitingNCT06731231Phase 1/2
• Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG StudyCompletedNCT06721442Phase 4
• The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.CompletedNCT06719661Not applicable
• Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep ApneaCompletedNCT06690723Phase 3
• Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient DepartmentActive, not recruitingNCT06683053Phase 3
• A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese ParticipantsCompletedNCT06651021Phase 1
• Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes MellitusCompletedNCT06632561Phase 4
• Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial InfarctionStatus unknownNCT06619600Phase 3
• Antithrombotic Activities of Sotagliflozin vs. EmpagliflozinCompletedNCT06618976Phase 4
• Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients with Acute Myocardial InfarctionCompletedNCT06615674Phase 4
• A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney DiseaseActive, not recruitingNCT06610526Phase 4
• Effect of the Use of Dapagliflozin in Patients With Refractory Heart FailureActive, not recruitingNCT06578520Phase 4
• Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 DiabetesActive, not recruitingNCT06532682Phase 4
• A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyActive, not recruitingNCT06481891Phase 3
• The Role of SGLT2i in Management of Moderate ASCompletedNCT06469645Phase 2/3
• Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial FibrillationCompletedNCT06433479Not applicable
• Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed ConditionsCompletedNCT06399068Phase 1
• Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting ConditionsCompletedNCT06399055Phase 1
• Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)Active, not recruitingNCT06391450Phase 4
• Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.CompletedNCT06383832Phase 4
• Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.CompletedNCT06374043Phase 4
• MASLD in Primary Hypothyroidism and Efficacy of DapaglifozinActive, not recruitingNCT06373523Early Phase 1
• Empagliflozin for No-reflow Phenomenon in PCI for STEMIActive, not recruitingNCT06342141Phase 2
• Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic PatientsCompletedNCT06326034Phase 4
• Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)Active, not recruitingNCT06317051Phase 3
• Empagliflozin Versus Vildagliptin in CAD Patients With T2DMCompletedNCT06313008Not applicable
• The Efficacy and Tolerability of Canagliflozin in Healthy IndividualCompletedNCT06301529Phase 4
• Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)WithdrawnNCT06280976Phase 4
• Adding SGLt2 Inhibitors to Patients With Type 2 DiabetesCompletedNCT06268977Phase 4
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Active, not recruitingNCT06268873Phase 3
• Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart DiseaseActive, not recruitingNCT06260059Phase 4
• Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of HyperglycemiaCompletedNCT06187285Not applicable
• Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting ConditionCompletedNCT06180109Phase 1
• EMPagliflozin After Aortic Valve ReplacementCompletedNCT06171802Phase 4
• To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008CompletedNCT06165965Phase 1
• Impact of SGLT2 Inhibitors in Heart Transplant RecipientsStatus unknownNCT06147271Phase 2
• Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese PatientCompletedNCT06145360Phase 4
• Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes PatientsCompletedNCT06144788Phase 2
• Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or MultimorbidityCompletedNCT06140108Phase 2/3
• Bioequivalence Study of Dapagliflozin 10 mg Film-coated TabletsCompletedNCT06127212Not applicable
• Empagliflozin to Prevent Post-Operative Atrial FibrillationStatus unknownNCT06124937Phase 3
• SGLT2 Inhibitors After Acute Kidney Injury With Indications PilotTerminatedNCT06124924Early Phase 1
• The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusCompletedNCT06117137Phase 3
• Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility StudyCompletedNCT06111768Phase 2
• Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial FibrillationActive, not recruitingNCT06111443Phase 2/3
• Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialCompletedNCT06094920Phase 4
• Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Active, not recruitingNCT06087835Phase 3
• Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesWithdrawnNCT06083675Phase 3
• Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsCompletedNCT06065280Not applicable
• A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.CompletedNCT06063109Phase 1
• Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationActive, not recruitingNCT06027307Phase 3
• Clinical Value of Adding Dapagliflozin in Patients With Nephrotic SyndromeCompletedNCT06026787Phase 4
• Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic OutcomesStatus unknownNCT06021145Phase 4
• Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)CompletedNCT06012279Phase 4
• The Effect of Dapagliflozin on Weight Loss in Obese Adults Without DiabetesActive, not recruitingNCT06000462Phase 4

← Sodium-Glucose Transporter 2 Inhibitors overview